Loading…
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | - | - | - | - | - | 0.0% | 0.0% |
| 2024 | - | - | - | - | - | 0.0% | 0.0% |
| 2023 | $3M | $-46M | $-46M | $-37M | -238.4% | -14.6% | 50.6% |
| 2022 | $3M | $-29M | $-31M | $-31M | -338.3% | -45.1% | 78.0% |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | 5.83 | 3.20 | 2.73 | - | - |
| Operating Revenue | 5.83 | 3.20 | 2.73 | - | - |
| Cost Of Revenue | 3.93 | 2.90 | 1.86 | - | - |
| Gross Profit | 1.91 | 0.30 | 0.88 | - | - |
| Operating Expense | 18.23 | 31.79 | 47.53 | - | - |
| Research And Development | 9.99 | 17.59 | 30.89 | - | - |
| Selling General And Administration | 9.14 | 15.21 | 17.05 | - | - |
| Total Expenses | 22.15 | 34.69 | 49.39 | - | - |
| Operating Income | -16.32 | -31.49 | -46.66 | - | - |
| Total Operating Income As Reported | -16.86 | -31.11 | -48.14 | - | - |
| EBITDA | -15.50 | -29.14 | -45.54 | - | - |
| Normalized EBITDA | -15.61 | -30.50 | -44.28 | - | - |
| EBIT | -16.14 | -29.92 | -46.70 | - | - |
| Interest Income | 0.07 | 0.21 | 0.43 | - | - |
| Interest Expense | 1.03 | 0.65 | 0.07 | - | - |
| Net Interest Income | -0.97 | -0.44 | 0.36 | - | - |
| Other Non Operating Income Expenses | 0.01 | 0 | 0.79 | - | - |
| Other Income Expense | 0.12 | 1.36 | -0.47 | - | - |
| Interest Income Non Operating | 0.07 | 0.21 | 0.43 | - | - |
| Interest Expense Non Operating | 1.03 | 0.65 | 0.07 | - | - |
| Net Non Operating Interest Income Expense | -0.97 | -0.44 | 0.36 | - | - |
| Pretax Income | -17.17 | -30.56 | -46.76 | - | - |
| Tax Provision | 0 | 0 | 0 | - | - |
| Tax Rate For Calcs | 0 | 0 | 0 | - | - |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | - | - |
| Net Income Continuous Operations | -17.17 | -30.56 | -46.76 | - | - |
| Net Income From Continuing And Discontinued Operation | -17.17 | -30.56 | -46.02 | - | - |
| Net Income From Continuing Operation Net Minority Interest | -17.17 | -30.56 | -46.02 | - | - |
| Net Income | -17.17 | -30.56 | -46.02 | - | - |
| Net Income Common Stockholders | -17.17 | -30.56 | -46.02 | - | - |
| Net Income Including Noncontrolling Interests | -17.17 | -30.56 | -46.76 | - | - |
| Normalized Income | -17.28 | -31.92 | -44.76 | - | - |
| Diluted NI Availto Com Stockholders | -17.17 | -30.56 | -46.02 | - | - |
| Basic Average Shares | - | 13.36 | 15.61 | 20.25 | 36.91 |
| Diluted Average Shares | - | 13.36 | 15.61 | 20.25 | 36.91 |
| Reconciled Depreciation | 0.64 | 0.77 | 1.16 | - | - |
| Reconciled Cost Of Revenue | 3.37 | 2.35 | 1.02 | - | - |
| Total Unusual Items | 0.11 | 1.36 | -1.26 | - | - |
| Total Unusual Items Excluding Goodwill | 0.11 | 1.36 | -1.26 | - | - |
| Minority Interests | - | 0 | 0.74 | - | - |
| Special Income Charges | - | 0 | -0.63 | - | - |
| Other Special Charges | - | - | 0.13 | - | - |
| Gain On Sale Of Security | 0.11 | 1.36 | -0.63 | - | - |
| Depreciation Amortization Depletion Income Statement | 0.08 | 0.23 | 0.31 | - | - |
| Depreciation And Amortization In Income Statement | 0.08 | 0.23 | 0.31 | - | - |
| General And Administrative Expense | 8.72 | 14.41 | 15.96 | - | - |
| Other Gand A | 3.09 | 6.60 | 5.26 | - | - |
| Salaries And Wages | 5.13 | 7.17 | 9.86 | - | - |
| Gain On Sale Of Ppe | - | 0 | -0.50 | - | - |
| Insurance And Claims | 0.50 | 0.64 | 0.84 | - | - |
| Other Operating Expenses | -0.99 | -1.24 | -0.72 | - | - |
| Selling And Marketing Expense | 0.41 | 0.81 | 1.09 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Anteris Technologies Global Corp.this co. | AVR | $939M | - | 48.67 | -238.4% | - |
| Corvus Pharmaceuticals, Inc. | CRVS | $986M | -64.49 | 16.10 | -25.0% | -22.91 |
| InnovAge Holding Corp. | INNV | $977M | -32.24 | 4.16 | -12.9% | -102.40 |
| U.S. Physical Therapy, Inc. | USPH | $940M | 62.41 | 1.97 | 3.2% | 11.12 |
| Olema Pharmaceuticals, Inc. | OLMA |
| 2021 | $6M | $-15M | $-17M | $-15M | -163.1% | - | - |
| $933M |
| -5.74 |
| 1.95 |
| -33.9% |
| -4.99 |
| Nutex Health Inc. | NUTX | $930M | 13.13 | 2.82 | 21.5% | 3.81 |
| ARS Pharmaceuticals, Inc. | SPRY | $901M | -5.26 | 7.88 | -149.9% | -5.66 |
| Annexon, Inc. | ANNX | $893M | -4.32 | 4.22 | -97.7% | -3.54 |
| Pacira BioSciences, Inc. | PCRX | $892M | 126.89 | 1.29 | 1.0% | 8.75 |
| Peer Median | - | -4.79 | 3.49 | -18.9% | -4.26 | |